AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02065596
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
Trial: NCT01313520
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
Trial: NCT03497429
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib capsule
Trial: NCT03264989
Drug: crizanlizumab
RxNorm normalized name: Crizanlizumab
DrugBank: Crizanlizumab (DB15271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
Trial: NCT01653912
Drug: GSK2110183 in combination with carboplatin and paclitaxel
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
Trial: NCT00423085
Drug: Rivastigmine transdermal patch
RxNorm normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
Trial: NCT00254293
Drug: Abatacept or Placebo (both as IV & SC Solution)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Trial: NCT00254293
Drug: Abatacept or Placebo (both as IV & SC Solution)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Trial: NCT00254293
Drug: Abatacept or Placebo (both as IV & SC solution)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Trial: NCT00933231
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard dose, Oral
Trial: NCT00933231
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose, Oral
Trial: NCT00933231
Drug: Cellcept
RxNorm normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT00933231
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00933231
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03592212
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Measurement of bronchodilator response (BDR)
Trial: NCT04481048
Drug: N-Acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
Trial: NCT02080026
Drug: chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
Trial: NCT02080026
Drug: atovaquone/proguanil
RxNorm normalized name: ATOVAQUONE/PROGUANIL
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg
Trial: NCT01798550
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing
Trial: NCT01968213
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
Trial: NCT00969033
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan
Trial: NCT02105948
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
Trial: NCT03498248
Drug: lenograstim
RxNorm normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
Trial: NCT03989817
Drug: Vasoactive Intestinal Peptide (VIP) and Saline
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
Trial: NCT00254293
Drug: Abatacept or Placebo (both as IV & SC solution)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Trial: NCT00254293
Drug: Abatacept or Placebo (both as IV & SC solution)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Trial: NCT04323436
Drug: Spartalizumab
RxNorm normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution for infusion
Trial: NCT04323436
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet
Trial: NCT04323436
Drug: spartalizumab placebo
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextrose 5% in water (D5W) for infusion
Trial: NCT03500874
Drug: FUDR
RxNorm normalized name: FUDR
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
Trial: NCT03500874
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
Trial: NCT03500874
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180mg/m2
Trial: NCT03325712
Drug: BI 705564
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03325712
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for injection
Trial: NCT00202163
Drug: DHEA
RxNorm normalized name: DHEA
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00254293
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
Trial: NCT02163993
Drug: Galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SQ
Trial: NCT01487096
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: film-coated tablet~oral administration
Trial: NCT01898338
Drug: Fosfomycin 2gr/6h iv
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01898338
Drug: Daptomycin 10mg/kg/24h iv
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01289067
Drug: Satraplatin
RxNorm normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
Trial: NCT01042457
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
Trial: NCT01689116
Drug: Bardoxolone Methyl 20mg
RxNorm normalized name: methylal
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01689116
Drug: Bardoxolone Methyl 80mg
RxNorm normalized name: methylal
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01689116
Drug: Bardoxolone Methyl Placebo
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01689116
Drug: Moxifloxacin 400mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01689116
Drug: Moxifloxacin Placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06559488
Drug: Bevacizumab Injection [Avastin]
RxNorm normalized name: bevacizumab Injection [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
Trial: NCT04039516
Drug: Lutathera
RxNorm normalized name: Lutathera
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 4 infusions of Lutathera to be administered every 8 weeks.
Trial: NCT00435370
Drug: Tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day
Trial: NCT00435370
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6mg/day
Trial: NCT01700608
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
Trial: NCT00627705
Drug: N-Acetyl Cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous).
Trial: NCT05997004
Drug: Glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
Trial: NCT01176903
Drug: Glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurized metered dose inhaler
Trial: NCT01176903
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation powder, hard capsule
Trial: NCT02727101
Drug: perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
Trial: NCT03620942
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min.
Trial: NCT03620942
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min.
Trial: NCT00866840
Drug: riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg orally twice daily
Trial: NCT01561248
Drug: polyethylene glycol solution for daily bowel lavage.
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
Trial: NCT00290823
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablet taken orally twice daily
Trial: NCT00290823
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6mg or 8mg taken daily
Trial: NCT00290823
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg tablet taken orally daily
Trial: NCT03848533
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)
Trial: NCT00063947
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00063947
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02599194
Drug: 18F-FSPG
RxNorm normalized name: 18F-FSPG
DrugBank: Florilglutamic acid F-18 (DB15041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV)
Trial: NCT02599194
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV)
Trial: NCT01410448
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
Trial: NCT01410448
Drug: Mycophenolate sodium
RxNorm normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
Trial: NCT01410448
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
Trial: NCT01308580
Drug: Cabazitaxel (XRP6258)
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous
Trial: NCT01308580
Drug: Prednisone (or Prednisolone)
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT00360529
Drug: flibanserin
RxNorm normalized name: Flibanserin
DrugBank: Flibanserin (DB04908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Trial: NCT00505739
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg by mouth (PO) Daily x 4 Weeks
Trial: NCT02186951
Drug: Amoxicillin - clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
Trial: NCT01408160
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03331666
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
Trial: NCT02581566
Drug: Intrathecal Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
Trial: NCT02581566
Drug: Intraarticular Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
Trial: NCT02581566
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal Bupivacaine
Trial: NCT00681967
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg; oral
Trial: NCT00681967
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg; oral
Trial: NCT03695640
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Addition of magnesium sulfate as an adjuvant to levobupivacaine
Trial: NCT00199134
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Size of the tumor is followed
Trial: NCT01523314
Drug: dexamethasone - Cyclodextrin eye drops
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
Trial: NCT00985556
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV